Share

Interview of Prof. Meunier for EJC News Focus

Director General Françoise Meunier discusses the challenges faced today by clinical researchers in cancer. She outlines key changes needed in the ongoing revision of the Clinical Trials Directive – in particular, the need for a risk-based approach to trials, and for Member States to harmonise their implementation of the Directive – and she describes the essential features of a suggested new partnership between academia and industry. She also covers the role EORTC will continue to play in developing the early careers of investigators.

 

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023